Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...

Net income was up a robust 525% year over year, rising to $125 million. BioMarin Pharmaceutical exceeded earnings and revenue expectations in its Q4 2024 financial results. BioMarin Pharmaceutical ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

A slimmed-down BioMarin started the new year with a bang, hitting the annual J.P. Morgan Healthcare Conference with the goal of tapping its skillset to strike deals that bolster its pipeline of ...

BioMarin is amassing a portfolio of genetic-disease therapeutics, making historical comparisons with Genzyme (acquired by Sanofi) difficult to avoid. Commercialization and research and development ...

BioMarin's has signed the first contract with an insurer in Germany for Roctavian, its recently approved gene therapy for haemophilia A, as it tests out its outcomes-based agreement (OBA ...

BioMarin Pharmaceutical beat analysts’ revenue ... The US Central Bank is now cutting rates. That, plus the election of Donald Trump in November 2024, sent markets even higher, and while some ...

CEO Alexander Hardy emphasized that 2024 marked a year of record growth and profitability for BioMarin, with revenue increasing by 18% year-over-year and non-GAAP diluted EPS up 69%. He ...

BioMarin’s Q4 adjusted EPS rose to $0.92, surpassing the $0.53 consensus. 2025 sales guidance set at $3.1 billion-$3.2 billion, with EPS expected at $4.20-$4.40. Join Nic Chahine live on ...

But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with ... San Rafael, CA-based BioMarin Pharmaceutical Inc. focuses on ...

BioMarin Pharmaceutical (NASDAQ:BMRN), a leader in developing innovative therapies for rare genetic disorders, reported fourth-quarter 2024 financial results on Wednesday, Feb. 19, that topped ...